Solux Co. Ltd Asset Resilience Ratio
Solux Co. Ltd asset resilience ratio. Solux Co. Ltd (290690) has an Asset Resilience Ratio of 0.51% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 290690 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Solux Co. Ltd (2018–2025)
Asset resilience ratio of Solux Co. Ltd from 2018 to 2025. This chart shows how Solux Co. Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Solux Co. Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Solux Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 290690 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.00 Billion | 0.51% |
| Total Liquid Assets | ₩1.00 Billion | 0.51% |
Asset Resilience Insights
- Limited Liquidity: Solux Co. Ltd maintains only 0.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Solux Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Solux Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Solux Co. Ltd Asset Resilience Ratio by Year (2018–2025)
Solux Co. Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Solux Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.71% | ₩1.00 Billion ≈ $677.69K |
₩141.59 Billion ≈ $95.95 Million |
-13.40pp |
| 2023-12-31 | 14.11% | ₩22.60 Billion ≈ $15.32 Million |
₩160.17 Billion ≈ $108.54 Million |
-1.33pp |
| 2022-12-31 | 15.44% | ₩10.56 Billion ≈ $7.16 Million |
₩68.41 Billion ≈ $46.36 Million |
+11.64pp |
| 2021-12-31 | 3.80% | ₩2.81 Billion ≈ $1.90 Million |
₩73.88 Billion ≈ $50.07 Million |
-12.54pp |
| 2020-12-31 | 16.34% | ₩10.88 Billion ≈ $7.37 Million |
₩66.57 Billion ≈ $45.11 Million |
+4.71pp |
| 2019-12-31 | 11.63% | ₩5.61 Billion ≈ $3.80 Million |
₩48.23 Billion ≈ $32.68 Million |
-6.90pp |
| 2018-12-31 | 18.53% | ₩8.11 Billion ≈ $5.50 Million |
₩43.77 Billion ≈ $29.66 Million |
-- |
About Solux Co. Ltd
ARIBIO Holdings Inc. manufactures and supplies indoor, outdoor, and special purpose lighting products in South Korea and internationally. The company was formerly known as Solux Co., Ltd. and changed its name to ARIBIO Holdings Inc. in July 2026. ARIBIO Holdings Inc. was founded in 1995 and is headquartered in Gongju-si, South Korea.